Anna Ermakova
Research Scientist at Beckley Psytech and psychedelic research contributor
Data updated
Research Footprint
Anna Ermakova appears in 6 tracked papers (2021–2026), most studied alongside 5-MeO-DMT and Placebo, across Safety & Risk Management, Depressive Disorders and Healthy Volunteers.
Most-cited paper: A narrative synthesis of research with 5-MeO-DMT (81 citations).
Frequent co-authors: Fiona Dunbar, Mathieu Seynaeve and James Rucker.
Background & Research
Anna O. Ermakova is also referred to publicly as Anya Ermakova. Public profiles and articles describe her as a research scientist working with Beckley Psytech, with interests spanning nature conservation, ethnobotany, neuroscience, and psychiatry. She has contributed to 5-MeO-DMT research across review, phenomenology, and clinical-trial publications.
Key Impact
She is an author on multiple influential 5-MeO-DMT clinical and review papers, helping build the evidence base for psychedelic therapies in depression and alcohol use disorder.
Collaboration Network
6 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Anna Ermakova is associated with.
Beckley Psytech
Private BiotechBeckley Psytech was a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the Beckley Foundation — the UK-based psychedelic research charity co-founded by Amanda Feilding. The company focused on developing novel proprietary psychedelic formulations, with its lead asset BPL-003, an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) for treatment-resistant depression. BPL-003 received FDA Breakthrough Therapy Designation and delivered positive Phase 2b results. In November 2025, Beckley Psytech merged with atai Life Sciences in an all-share transaction to form AtaiBeckley, with BPL-003 becoming the lead asset of the combined company.
View stakeholder →King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →Chacruna
Non-ProfitChacruna is a nonprofit psychedelic education and advocacy platform based in the United States with global reach through online publishing, courses, conferences, and multilingual programming. Its work centers on psychedelic plant medicines, ethics, cultural justice, reciprocity, and Indigenous knowledge, with content and activities aimed at researchers, clinicians, educators, policy audiences, and the broader public. The organization says it bridges ceremony and science and makes academic knowledge more accessible through public-facing education. Chacruna plays an explicit role in psychedelic justice and policy-adjacent advocacy by foregrounding cultural context, equity, and protection of sacred plants and traditions. Current documented initiatives include the Indigenous Reciprocity Initiative of the Americas, which supports community-led Indigenous projects, the Psychedelic Culture conference, the bilingual Chacruna Latinoamérica platform, and courses on diversity, culture, social justice, ceremony, ethics, and reciprocity. These activities make it a potential partner for researchers, clinicians, funders, and policy groups seeking cultural consultation, educational programming, and community-centered collaboration.
View stakeholder →